Imiquimod 5 % Cream

Phase 2Completed
0 views this week 0 watching💤 Quiet
Interest: 32/100
32
Hype Score

Development Stage

Pre-clinical
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Actinic Keratosis

Conditions

Actinic Keratosis

Trial Timeline

Nov 1, 2002 → Sep 1, 2005

About Imiquimod 5 % Cream

Imiquimod 5 % Cream is a phase 2 stage product being developed by Viatris for Actinic Keratosis. The current trial status is completed. This product is registered under clinical trial identifier NCT00189267. Target conditions include Actinic Keratosis.

What happened to similar drugs?

7 of 20 similar drugs in Actinic Keratosis were approved

Approved (7) Terminated (1) Active (13)
fluorouracil cream 0.5%SanofiApproved
Imiquimod + DiclofenacViatrisApproved
Imiquimod + DiclofenacViatrisApproved
Tirbanibulin 2.5 mg ointmentAlmirallApproved
TirbanibulinAlmirallApproved
Ameluz 10% Topical GelBiofronteraApproved

Hype Score Breakdown

Clinical
12
Activity
8
Company
12
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT00189267Phase 2Completed

Competing Products

20 competing products in Actinic Keratosis

See all competitors